Morbus Alzheimer - Rivastigmine: Approval for the first transdermal application granted in Europe

被引：0
|
作者：
不详
机构：
来源：
NERVENARZT | 2007年 / 78卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A1 / A3
页数：3
相关论文
共 50 条
  • [41] From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease
    Rene, R.
    Ricart, J.
    Hernandez, B.
    NEUROLOGIA, 2014, 29 (02): : 86 - 93
  • [42] IDEAL: A 6-month placebo-controlled study of the first transdermal patch in Alzheimer's disease rivastigmine patch versus capsule
    Winblad, Bengt
    Cummings, Jeffrey
    Zechner, Stefanie
    Ros, Jacqueline
    Nagel, Jennifer
    Bernhard, Gudrun
    Lane, Roger
    ANNALS OF NEUROLOGY, 2006, 60 : S56 - S56
  • [43] Dose Effects Associated with Rivastigmine Transdermal Patch in Patients with Mild-to-Moderate Alzheimer's Disease
    Grossberg, George T.
    Somogyi, Monique
    Meng, Xiangyi
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2011, 19 (03): : S121 - S122
  • [44] A Cost-Utility Analysis of Rivastigmine Transdermal System for the Treatment of Patients with Alzheimer's Disease in Mexico
    Cruz, Samaria
    Briones, Bernardo
    Garcia-Contreras, Fernando
    NEUROLOGY, 2011, 76 (09) : A231 - A231
  • [45] Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease
    Muhlack, S
    Przuntek, H
    Müller, T
    PHARMACOPSYCHIATRY, 2006, 39 (01) : 16 - 19
  • [46] Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
    Tsuno, Norifumi
    Mori, Takahiro
    Ishikawa, Ichiro
    Bando, Nobuyasu
    Park, Haeyoung
    Matsumoto, Yoshito
    Mori, Itsuko
    Tanaka, Mariko
    Hirano, Takayuki
    Nakamura, Yu
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2019, 19 (07) : 571 - 576
  • [47] Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease
    Moretti, Davide V.
    Frisoni, Giovanni B.
    Binetti, Giuliano
    Zanetti, Orazio
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [48] Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice
    Lopez-Pousa, Secundino
    Javier Arranz, Francisco
    PATIENT PREFERENCE AND ADHERENCE, 2013, 7 : 47 - 54
  • [49] Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease
    Grossberg, G. T.
    Olin, J. T.
    Somogyi, M.
    Meng, X.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (04) : 465 - 471
  • [50] First Donepezil Transdermal Patch Approved for Alzheimer Disease
    Larkin, Howard D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (17): : 1642 - 1642
12345